Clinical assessment and management of dyslipidemia in patients with chronic kidney disease

Clinical and Experimental Nephrology

Volumn 16, Issue 4, 2012, Pages 522-529

  Nitta, Kosaku ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Cardiovascular disease; Chronic kidney disease; Dyslipidemia; GFR; Statin

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CREATININE; EZETIMIBE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ALBUMINURIA; ANEMIA; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG DOSE INCREASE; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HEMODIALYSIS; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; MALNUTRITION; NONHUMAN; OXIDATIVE STRESS; PERITONEAL DIALYSIS; PROTEINURIA; REVIEW; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

CARDIOVASCULAR DISEASES; COMORBIDITY; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84865122860     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-012-0655-x     Document Type: Review

References (78)

1. National Kidney Foundation 2002 K/DOQI clinical practice guidelines for chronic kidney disease: evidence, classification, and stratification Am J Kidney Dis 39 Suppl 1 S1 S266
2. AT Whaley-Connell JR Sowers LA Stevens SI McFarlane MG Shlipak KC Norris, et al. 2008 CKD in the Unites States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004 Am J Kidney Dis 51 4 Suppl 2 S13 S20 18359403 10.1053/j.ajkd.2007.12.016 1:CAS:528:DC%2BD1cXltl2msLs%3D (Pubitemid 351417310)
3. AS Go GM Chertow D Fan CE McCulloch CY Hsu 2004 Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 1296 1305 15385656 10.1056/NEJMoa041031 1:CAS:528:DC%2BD2cXnvFSgtr8%3D (Pubitemid 39268908)
4. Ninomiya T, Kiyohara Y, Kubo M, Tanizaki Y, Doi Y, Okubo K, et al. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int. 2005; 68:228-36. (Pubitemid 43181380)
5. F Irie H Iso T Sairenchi N Fukasawa K Yamagishi S Ikehara, et al. 2006 The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population Kidney Int 69 1264 1271 16501489 10.1038/sj.ki.5000284 1:CAS:528:DC%2BD28XivFOmt78%3D
6. S Van der Zee U Baber S Elmariah J Winston V Fuster 2009 Cardiovascular risk factors in patients with chronic kidney disease Nat Rev Cardiol 6 580 589 19621012 10.1038/nrcardio.2009.121
7. J Kendrick MB Chonchol 2008 Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease Nat Clin Pract Nephrol 4 672 681 18825155 10.1038/ncpneph0954
8. TJ Wang P Gona MG Larson MG Larson GH Tofler D Levy, et al. 2006 Multiple biomarkers for the prediction of first major cardiovascular events and death N Engl J Med 355 2631 2639 17182988 10.1056/NEJMoa055373 1:CAS:528: DC%2BD28XhtlGhtLvJ (Pubitemid 44969122)
9. H Honda AR Qureshi O Heimburger P Barany K Wang R Pecoits-Fiho, et al. 2006 Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD Am J Kidney Dis 47 139 148 16377395 10.1053/j.ajkd.2005.09.014 1:CAS:528:DC%2BD28Xpt1elsw%3D%3D (Pubitemid 41828276)
10. F Addabbo F Mallamaci D Leonardis R Tripepi G Tripepi MS Goliqorsky, et al. 2007 Searching for biomarker patterns characterizing carotid atherosclerotic burden in patients with reduced renal function Nephrol Dial Transplant 22 3521 3526 17636056 10.1093/ndt/gfm418 1:CAS:528:DC%2BD2sXhtlOqsbbJ (Pubitemid 350212487)
11. V Tsimihodimos E Dounousi KC Siamopoulos 2008 Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment Am J Nephrol 28 958 973 18612199 10.1159/000144024 1:CAS:528:DC%2BD1cXht1SlsbrK
12. GA Kaysen 2009 Lipid and lipoprotein metabolism in chronic kidney disease J Ren Nutr 19 73 77 19121776 10.1053/j.jrn.2008.10.011 1:CAS:528: DC%2BD1MXksl2rsL0%3D
13. F Kronenberg 2005 Dyslipidemia and nephrotic syndrome: recent advances J Ren Nutr 15 195 203 15827892 10.1053/j.jrn.2004.10.003
14. BC Kwan F Kronenberg S Beddhu AK Cheung 2007 Lipoprotein metabolism and lipid management in chronic kidney disease J Am Soc Nephrol 18 1246 1261 17360943 10.1681/ASN.2006091006 1:CAS:528:DC%2BD2sXkslSrsb0%3D (Pubitemid 46536911)
15. PO Attman O Samuelsson 2009 Dyslipidemia of kidney disease Curr Opin Lipidol 20 293 299 19512921 10.1097/MOL.0b013e32832dd832 1:CAS:528: DC%2BD1MXotFCjurw%3D
16. Prinsen BH, de Sain-van der Velden MG, de Koning EJ, Koomans HA, Berger R, Rabelink TJ. Hypertriglyceridemia in patients with chronic renal failure: possible mechanisms. Kidney Int Suppl. 2003; 84:S121-4 (Pubitemid 36513391)
17. DT Chan GK Dogra AB Irish EM Ooi PH Barrett DC Chan, et al. 2009 Chronic kidney disease delays VLDL apoB-100 particle catabolism: potential role of apo C-III J Lipid Res 50 2524 2531 19542564 10.1194/jlr.P900003-JLR200 1:CAS:528:DC%2BD1MXhsVyrsbzP
18. JA Charlesworth AD Kriketos JE Jones JH Erlich LV Campbell PW Peake 2005 Insulin resistance and postprandial triglyceride levels in primary renal disease Metabolism 54 821 828 15931621 10.1016/j.metabol.2005.01.028 1:CAS:528:DC%2BD2MXks1eitrc%3D (Pubitemid 40725332)
19. K Liang ND Vaziri 1997 Gene expression of LDL receptor, HMG-CoA reductase, and cholesterol-7 alpha-hydroxylase in chronic renal failure Nephrol Dial Transplant 12 1381 1386 9249773 10.1093/ndt/12.7.1381 1:CAS:528: DyaK2sXltlKmu70%3D (Pubitemid 27353027)
20. I Rajman L Harper D McPake MJ Kendall DC Wheeler 1998 Low-density lipoprotein subfraction profiles in chronic renal failure Nephrol Dial Transplant 13 2281 2287 9761510 10.1093/ndt/13.9.2281 1:CAS:528: DyaK1cXmsVCgs70%3D (Pubitemid 28416554)
21. CJ Deighan MJ Caslake M McConnell JM Boulton-Jones CJ Packard 2000 Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation Am J Kidney Dis 35 852 862 10793019 10.1016/S0272-6386(00)70255-1 1:CAS:528:DC%2BD3cXjsFaku7g%3D (Pubitemid 30238197)
22. A Kontush MJ Chapman 2006 Antiatherogenic small, dense HDL-guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 3 144 153 16505860 10.1038/ncpcardio0500 1:CAS:528:DC%2BD28Xis1yjtLs%3D
23. JP Despres I Lemieux GR Dagenais B Cantin B Lamarche 2000 HDL-cholesterol as a marker of coronary heart disease risk: the Quebec cardiovascular study Atherosclerosis 153 263 272 11164415 10.1016/S0021-9150(00)00603-1 1:CAS:528:DC%2BD3MXlslKqsg%3D%3D (Pubitemid 32120325)
24. PO Attman O Samuelsson P Alaupovic 1993 Lipoprotein metabolism and renal failure Am J Kidney Dis 21 573 592 8503411 1:STN:280:DyaK3s3ns1yntA%3D%3D (Pubitemid 23178473)
25. ND Vaziri G Deng K Liang 1999 Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure Nephrol Dial Transplant 14 1462 1466 10383008 10.1093/ndt/14.6.1462 1:CAS:528:DyaK1MXjvFGqt7Y%3D (Pubitemid 29241738)
26. ND Vaziri K Liang JS Parks 2001 Down-regulation of hepatic lecithin:cholesterol acyltransferase gene expression in chronic renal failure Kidney Int 59 2192 2196 11380821 1:CAS:528:DC%2BD3MXks1Kltbs%3D (Pubitemid 32467611)
27. H Kimura R Miyazaki T Imura S Masunaga S Suzuki F Gejyo, et al. 2003 Hepatic lipase mutation may reduce vascular disease prevalence in hemodialysis patients with high CETP levels Kidney Int 64 1829 1837 14531818 10.1046/j.1523-1755.2003.00285.x 1:CAS:528:DC%2BD3sXpsVCrt7c%3D (Pubitemid 37323714)
28. H Honda M Ueda S Kojima S Mashiba H Suzuki N Hosaka, et al. 2010 Oxidized high-density lipoprotein is associated with protein-energy wasting in maintenance hemodialysis patients Clin J Am Soc Nephrol 5 1021 1028 20395357 10.2215/CJN.06110809 1:CAS:528:DC%2BC3cXptV2mtL0%3D
29. S Lewington G Whitlock R Clarke P Sherliker J Emberson J Halsey, et al. 2007 Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55, 000 vascular deaths Lancet 370 1829 1839 18061058 10.1016/S0140-6736(07)61778-4 (Pubitemid 350180032)
30. EG Lowrie NL Lew 1990 Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities Am J Kidney Dis 15 458 482 2333868 1:STN:280:DyaK3c3ktVaitg%3D%3D (Pubitemid 20174016)
31. K Kalantar-Zadeh G Block MH Humphreys JD Kopple 2003 Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients Kidney Int 63 793 808 12631061 10.1046/j.1523-1755.2003.00803.x (Pubitemid 36315558)
32. T Shoji Y Nishizawa 2005 Chronic kidney disease as a metabolic syndrome with malnutrition-need for strict control of risk factors Intern Med 44 179 187 15805704 10.2169/internalmedicine.44.179 (Pubitemid 40575895)
33. MJ Sarnak AS Levey AC Schoolwerth J Coresh B Culleton LL Hamm, et al. 2003 Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Circulation 108 2154 2169 14581387 10.1161/01.CIR.0000095676.90936.80 (Pubitemid 37337595)
34. T Shoji I Masakane Y Watanabe K Iseki 2011 Committee of Renal Data Registry, Japanese Society for Dialysis Therapy. Elevated non-high-density lipoprotein cholesterol (Non-HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients Clin J Am Soc Nephrol 6 1112 1120 21511840 10.2215/CJN.09961110 1:CAS:528:DC%2BC3MXotFynur0%3D
35. A Kitamura H Noda M Nakamura M Kiyama T Okada H Imano, et al. 2011 Association between non-high-density lipoprotein cholesterol levels and the incidence of coronary heart disease among Japanese: the Circulatory Risk in Communities Study (CIRCS) J Atheroscler Thromb 18 454 463 21378473 10.5551/jat.7237 1:CAS:528:DC%2BC3MXosleqtbg%3D
36. CP Kovesdy SM George JE Anderson K Kalantar-Zadeh 2009 Outcome predictability of biomarkers of protein-energy wasting and inflammation in moderate and advanced chronic kidney disease Am J Clin Nutr 90 407 414 19535427 10.3945/ajcn.2008.27390 1:CAS:528:DC%2BD1MXpt1Wqsbw%3D
37. J Bergstrom B Lindholm 1998 Malnutrition, cardiac disease, and mortality: an integrated point of view Am J Kidney Dis 32 834 841 9820457 10.1016/S0272-6386(98)70148-9 1:STN:280:DyaK1M%2Fjs1ensQ%3D%3D (Pubitemid 28516318)
38. J Zimmermann S Herrlinger A Pruy T Metzger C Wanner 1999 Inflammation enhances cardiovascular risk and mortality in hemodialysis patients Kidney Int 55 648 658 9987089 10.1046/j.1523-1755.1999.00273.x 1:STN:280: DyaK1M7ktFGlsA%3D%3D (Pubitemid 29082891)
39. K Iseki N Kawazoe K Fukiyama 1993 Serum albumin is a strong predictor of death in chronic dialysis patients Kidney Int 44 115 119 8355451 10.1038/ki.1993.220 1:STN:280:DyaK3szmtVCktQ%3D%3D (Pubitemid 23198033)
40. N Amemiya T Ogawa K Otsuka Y Ando K Nitta 2011 Comparison of serum albumin, serum C-reactive protein, and pulse wave velocity as predictors of 4-year mortality of chronic hemodialysis patients J Atheroscler Thromb 18 1071 1079 21921415 10.5551/jat.10397 1:CAS:528:DC%2BC38XjtVKqtrc%3D
41. RN Foley PS Parfrey JD Harnett GM Kent DC Murray PE Barre 1996 Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease J Am Soc Nephrol 7 728 736 8738808 1:STN:280:DyaK28zjt1yqsQ%3D%3D (Pubitemid 27466006)
42. S Soriano L Gonzalez A Martin-Malo M Rodriguez P Aljama 2007 C-reactive protein and low albumin are predictors of morbidity and cardiovascular events in chronic kidney disease (CKD) 3-5 patients Clin Nephrol 67 352 357 17598370 1:CAS:528:DC%2BD2sXovVOnt70%3D (Pubitemid 46894799)
43. LS Dalrymple GA Kaysen 2008 The effect of lipoproteins on the development and progression of renal disease Am J Nephrol 28 723 731 18434711 10.1159/000127980 1:CAS:528:DC%2BD1cXhtVKmsLnE
44. NJ Brunskill 2004 Albumin signals the coming of age of proteinuric nephropathy J Am Soc Nephrol 15 504 505 14747400 10.1097/01.ASN.0000112912. 40303.81 (Pubitemid 38140794)
45. H Scheuer W Gwinner J Hohbach EF Grone RP Brandes E Malle, et al. 2000 Oxidant stress in hyperlipidemia-induced renal damage Am J Physiol Renal Physiol 78 F63 F74
46. ND Vaziri 2006 Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences Am J Physiol Renal Physiol 290 F262 F272 16403839 10.1152/ajprenal.00099.2005 1:CAS:528:DC%2BD28XhsFKit7k%3D (Pubitemid 43724980)
47. P Muntner J Coresh JC Smith J Eckfeldt MJ Klag 2000 Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study Kidney Int 58 293 301 10886574 10.1046/j.1523-1755.2000.00165.x 1:CAS:528:DC%2BD3cXltVyjtbg%3D (Pubitemid 30429874)
48. O Samuelsson PO Attman C Knight-Gibson R Larsson H Mulec L Weiss, et al. 1998 Complex apolipoprotein B-containing lipoprotein particles are associated with a high rate of progression of human chronic renal insufficiency J Am Soc Nephrol 9 1482 1488 9697671 1:CAS:528:DyaK1cXltleiur0%3D (Pubitemid 28354559)
49. M Buemi M Senatore F Corica C Aloisi A Romeo E Cavallaro, et al. 2002 Statins and progressive renal disease Med Res Rev 22 76 84 11746177 10.1002/med.10000 1:CAS:528:DC%2BD38Xks1Shtg%3D%3D (Pubitemid 34019902)
50. T Nakamura C Ushiyama K Hirokawa S Osada T Inoue N Shimada, et al. 2002 Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis Nephrol Dial Transplant 17 798 802 11981066 10.1093/ndt/17.5.798 1:CAS:528:DC%2BD38XksVWitb4%3D (Pubitemid 34521130)
51. HM Colhoun DJ Betteridge PN Durrington GA Hitman HA Neil SJ Livingstone, et al. 2009 Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes study (CARDS) Am J Kidney Dis 54 810 819 19540640 10.1053/j.ajkd.2009.03.022 1:CAS:528:DC%2BD1MXhsFahs77I
52. H Nakamura K Mizuno Y Ohashi T Yoshida K Hirao Y Uchida 2009 Pravastatin and cardiovascular disease in moderate chronic kidney disease Atherosclerosis 206 512 517 19423108 10.1016/j.atherosclerosis.2009.03.031 1:CAS:528: DC%2BD1MXht1aju7nJ
53. VG Athyros DP Mikhailidis AA Papageorgiou AN Symeonidis AN Pehlivanidis VI Bouloukos, et al. 2004 The effect of statins versus untreated dyslipidemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atrorvastatin and coronary heart disease evaluation (GREACE) study J Clin Pathol 57 728 734 15220366 10.1136/jcp.2003.012989 1:CAS:528: DC%2BD2cXmslWktrs%3D (Pubitemid 38901488)
54. J Shepherd JJ Kastelein V Bittner P Deedwania A Breazna S Dobson, et al. 2007 Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study Clin J Am Soc Nephrol 2 1131 1139 17942759 10.2215/CJN.04371206 1:CAS:528:DC%2BD2sXhtlGgsbnE
55. S Sandhu N Wiebe LF Fried M Tonelli 2006 Statins for improving renal outcomes: a meta-analysis J Am Soc Nephrol 17 2006 2016 16762986 10.1681/ASN.2006010012 1:CAS:528:DC%2BD28Xntlanu78%3D (Pubitemid 44036185)
56. T Inoue H Ikeda T Nakamura S Abe I Taguchi M Kikuchi, et al. 2011 Potential benefit of statin therapy for dyslipidemia with chronic kidney disease: Fluvastatin Renal Evaluation Trial (FRET) Intern Med 50 1273 1278 21673461 10.2169/internalmedicine.50.4059
57. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis. 2003; 41:1-91.
58. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285:2486-97.
59. M Tonelli C Bohm S Pandeya J Gill A Levin BA Kiberd 2001 Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency Am J Kidney Dis 37 484 489 11228171 10.1053/ajkd.2001.22070 1:CAS:528:DC%2BD3MXit1ektL8%3D (Pubitemid 32195286)
60. K Harris M Thomas C Short R Moore 2002 Assessment of the efficiency of treatment of dyslipidaemia in renal outpatients J Nephrol 15 263 269 12113597 (Pubitemid 34830533)
61. C Baigent A Keech PM Kearney L Blackwell G Buck C Pollicino, et al. 2005 Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 1267 1278 16214597 10.1016/S0140-6736(05)67394-1 1:CAS:528:DC%2BD2MXhtVOlu7fM (Pubitemid 41416582)
62. M Landray C Baigent C Leaper D Adu P Altmann J Armitage, et al. 2006 The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD Am J Kidney Dis 47 385 395 16490616 10.1053/j.ajkd.2005.11.018 1:CAS:528: DC%2BD28XivVCku7g%3D (Pubitemid 43255171)
63. M Tonelli L Moye FM Sacks B Kiberd G Curhan 2003 Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency Ann Intern Med 138 98 104 12529091 1:CAS:528:DC%2BD3sXitVWksrk%3D (Pubitemid 36222496)
64. M Tonelli C Isles GC Curhan A Tonkin MA Pfeffer J Shepherd, et al. 2004 Effect of pravastatin on cardiovascular events in people with chronic kidney disease Circulation 110 1557 1563 15364796 10.1161/01.CIR.0000143892.84582.60 1:CAS:528:DC%2BD2cXnsVKqu70%3D (Pubitemid 39297976)
65. PA Lemos PW Serruys P de Feyter NF Mercado D Goedhart F Saia, et al. 2005 Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy) Am J Cardiol 95 445 451 15695126 10.1016/j.amjcard.2004.10.008 1:CAS:528:DC%2BD2MXptlClsg%3D%3D (Pubitemid 40247536)
66. H Holdaas C Wanner C Abletshauser C Gimpelewicz J Isaacsohn 2007 The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials Int J Cardiol 117 64 74 16889855 10.1016/j.ijcard.2006.06.003 (Pubitemid 46402940)
67. J Shepherd JJ Kastelein V Bittner P Deedwania A Breazna S Dobson, et al. 2008 Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study J Am Coll Cardiol 51 1448 1454 18402899 10.1016/j.jacc.2007.11.072 1:CAS:528:DC%2BD1cXks1Gmtbc%3D (Pubitemid 351471787)
68. MJ Koren MH Davidson DJ Wilson RS Fayyad A Zuckerman DP Reed 2009 Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD Am J Kidney Dis 53 741 750 19216014 10.1053/j.ajkd.2008.11.025 1:CAS:528:DC%2BD1MXlvFKqu7c%3D
69. PS Sever B Dahlof NR Poulter H Wedel G Beevers M Caulfield, et al. 2003 Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 361 1149 1158 12686036 10.1016/S0140-6736(03)12948-0 1:CAS:528:DC%2BD3sXis1yqu7o%3D (Pubitemid 36398384)
70. Navaneethan SD, Pansini F, Perkovic V, Manno C, Pellegrini F, Johnson DW, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2009; 2:CD007784.
71. SL Seliger NS Weiss DL Gillen B Kestenbaum A Ball DJ Sherrard, et al. 2002 HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients Kidney Int 61 297 304 11786112 10.1046/j.1523-1755.2002.00109.x 1:CAS:528:DC%2BD38XlslGlsQ%3D%3D (Pubitemid 34075157)
72. NA Mason GR Bailie S Satayathum JL Bragg-Gresham T Akiba T Akizawa, et al. 2005 HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients Am J Kidney Dis 45 119 126 15696451 10.1053/j.ajkd.2004.09.025 1:CAS:528:DC%2BD2MXhtVOrtrc%3D (Pubitemid 40038052)
73. AS Goldfarb-Rumyantzev AN Habib BC Baird LL Barenbaum AK Cheung 2007 The association of lipid-modifying medications with mortality in patients on long-term peritoneal dialysis Am J Kidney Dis 50 791 802 17954292 10.1053/j.ajkd.2007.07.023 1:CAS:528:DC%2BD2sXhtlOhtbnP (Pubitemid 47588556)
74. C Wanner V Krane W Marz M Olschewski HG Asmus W Kramer, et al. 2004 Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics Kidney Blood Press Res 27 259 266 15316128 10.1159/000080241 1:CAS:528:DC%2BD2cXntlWms7w%3D (Pubitemid 39279330)
75. C Wanner V Krane W Marz M Olschewski JF Mann G Ruf, et al. 2005 Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis N Engl J Med 353 238 248 16034009 10.1056/NEJMoa043545 1:CAS:528: DC%2BD2MXmt1Kms7s%3D (Pubitemid 41058323)
76. BC Fellstrom AG Jardine RE Schmieder H Holdaas K Bannister J Beutler, et al. 2009 Rosuvastatin and cardiovascular events in patients undergoing hemodialysis N Engl J Med 360 1395 1407 19332456 10.1056/NEJMoa0810177 1:CAS:528:DC%2BD1MXjvFCqtrY%3D
77. C Baigent MJ Landray C Reith J Emberson DC Wheeler C Tomson, et al. 2011 The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial Lancet 377 2181 2192 21663949 10.1016/S0140-6736(11)60739-3 1:CAS:528:DC%2BC3MXotVejsb0%3D
78. T Nakamura E Sato N Fujiwara Y Kawagoe Y Ueda T Suzuki, et al. 2010 Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner Pharmacol Res 61 58 61 19666118 10.1016/j.phrs.2009.07.011 1:CAS:528:DC%2BC3cXotlyn